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ABSTRACT 
A new series of thiazolylcoumarin derivatives was synthesized. The designed strategy embraced a molecular hy-
bridization approach which involves the combination of the thiazole and coumarin pharmacophores together. The 
new hybrid compounds were tested for in vitro antitumor efficacy over cervical (Hela) and kidney fibroblast (COS-
7) cancer cells. Compounds 5f, 5h, 5m and 5r displayed promising efficacy toward Hela cell line. In addition, 5h 
and 5r were found to be the most active candidates toward COS-7 cell line. The four active analogs, 5f, 5h, 5m 
and 5r were screened for in vivo antitumor activity over EAC cells in mice, as well as in vitro cytotoxicity toward 
W138 normal cells. Results illustrated that 5r has the highest in vivo activity, and that the four analogs are less 
cytotoxic than 5-FU toward W138 normal cells. In this study, 3D pharmacophore analysis was performed to in-
vestigate the matching pharmacophoric features of the synthesized compounds with trichostatin A. In silico studies 
showed that the investigated compounds meet the optimal needs for good oral absorption with no expected toxicity 
hazards. 
 
Keywords: thiazolylcoumarins, synthesis, antitumor activity, cytotoxic activity, 3D pharmacophore elucidation, 
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INTRODUCTION 
Cancer is a collection of related diseases. 
Cancer cells can metastasize and invade 
nearby tissues through blood stream or lym-
phatic system (Bagi, 2002). In general, cancer 
develops as a result of genetic changes, such 
as mutations in DNA. Cancer treatment in-
cludes radiation therapy, gene therapy and 
chemotherapy. Ideal anticancer agents would 
kill cancer cells without affecting normal tis-
sues. Therefore, the evolution of new safe an-
ticancer agents is a serious task for medicinal 
chemists.  
Histone deacetylases (HDACs) are Zn2+ 
dependent enzymes that catalyze the deacety-
lation of lysine residues located at the N-ε ter-
minal extensions of core histones resulting in 
chromatin condensation and transcriptional 
repression (Kouzarides, 2007). Eleven 
isoforms of HDACs are present in human 
(Gregoretti et al., 2004). Abnormalities in the 
deacetylation function of histones were rec-
ognized in various human tumors (Falkenberg 
and Johnstone, 2014). 
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Most HDACs inhibitors share common 
pharmacophoric features which can be exem-
plified by trichostatin A, a natural HDACs in-
hibitor. The common pharmacophore is com-
posed of three regions: zinc binding group 
(ZBG) that chelates Zn2+ at the active site of 
the enzyme, cap group which binds to the sur-
face of the active pocket and a linker between 
the ZBG and the cap group (Feng  et al., 
2013). Literature survey revealed the signifi-
cance of variations in the cap group (Bowers 
et al., 2009a, b) and the linker (Weerasinghe 
et al., 2008) on the HDACs inhibitory activ-
ity. However, the type of ZBG is believed to 
greatly affect the potency and isoform selec-
tivity of HDACs inhibitors (Methot et al., 
2008). Hydroxamic acid moiety is a typical 
ZBG which is common in numerous HDACs 
inhibitors. Due to the drawbacks of hydrox-
amate functional group which include non-
specific inhibition of all HDAC isoforms 
(Day and Cohen, 2013), diverse moieties such 
as thiols, benzamides, sulphamides and trithi-
ocarbonates were incorporated into diverse 
scaffolds and investigated for their capability 
as ZBG (Chen  et al., 2013; Di Micco et al., 
2013; Kawai and Nagata, 2012). Methyl ke-
tone was utilized as ZBG in the design of 
HDACs inhibitors (Ilies et al., 2011). Analo-
gously, we introduced coumarin moiety as a 
novel ZBG in the design of new HDACs in-
hibitors aiming to explore its effect as a non-
hydroxamate functional group. The hydrazi-
nylthiazole in the synthesized hybrids is im-
plied as a linker which projects the ZBG into 
the active site of HDACs. The cap region in 
the common pharmacophore has a strong con-
tribution to the overall binding affinity of 
HDACs inhibitors (Salisbury and Cravatt, 
2007). The common pharmacophoric features 
of trichostatin A and the proposed thiazolyl-
coumarin hybrids are illustrated in Figure 1.  
Literature revealed that numerous 
HDACs inhibitors have antitumor activity 
(Zain et al., 2010). Most of the reported 
HDACs inhibitors are hydroxamic acid deriv-
atives that exhibit non-specific inhibition of 
all HDAC isoforms (Day and Cohen, 2013). 
As a result, extensive research is directed to-
ward the development of non-hydroxamate 
HDACs inhibitors (Madsen et al., 2014).  
Coumarins of natural and synthetic ori-
gins constitute an important class of com-
pounds. They were proved to possess signifi-
cant therapeutic potential, including anti-
tumor activity (Morsy et al., 2017; Emami 
and Dadashpour, 2015; Klenkar and Molnar, 
2015; Amin et al., 2015; Pingaew et al., 
2014b; Sandhu et al., 2014; Liu et al., 2014; 
Li et al., 2014; Seidel et al., 2014; Sashidhara 
et al., 2010; Riveiro et al., 2010). On the same 
line, thiazole ring is a prominent skeleton in 
various bioactive molecules, including anti-
tumor compounds (Tay et al., 2017; Gomha et 
al., 2015; Abouzeid and El-Subbagh, 2015; 
Nofal et al., 2014; Rouf and Tanyeli, 2015; 
Prashanth et al., 2014; Yuan et al., 2014; 
Shitre et al., 2014; Tung et al., 2013). 
 
Figure 1: Common pharmacophoric features of trichostatin A and the proposed thiazolylcoumarin hy-
brids 5a-t 
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Moreover, literature survey indicated that thi-
azolylcoumarin hybrids (Abdul Rahman et 
al., 2016; Vaarla et al., 2015; Sreekanth et al., 
2014; Srimanth et al., 2002) and other 
aryl(heteroaryl)coumarin hybrids (Zhang et 
al., 2017; Pangal et al., 2017; Luo et al., 2017; 
Garazd et al., 2017; Holiyachi et al., 2016; 
Goel et al., 2015; Zhang et al., 2014; Kamal 
et al., 2009; Ganina et al., 2008) have promis-
ing antitumor activity.  
Hybrid approaches in drug design proved 
to offer advantages in drug-resistance (Hub-
schwerlen et al., 2003), introducing com-
pounds with improved biological activity 
(Pingaew et al., 2014a) as well as their contri-
bution in the development of promising 
agents with potent antitumor activity (Piens et 
al., 2014; Romagnoli et al., 2013). Therefore, 
we followed the hybridization strategy, com-
bining the thiazole and coumarin pharmaco-
phores together hoping to obtain new safe an-
titumor compounds. In addition, the design 
strategy embraced the profiling of diverse ar-
omatic moieties (representing the cap group) 
on the thiazolylcoumarin scaffold in order to 
study the relationship between the interaction 
forces of the cap group to the target receptor 
and the antitumor activity of the proposed thi-
azolylcoumarin hybrids. The new hybrid 
compounds were assessed for in vitro anti-
tumor activity, and the four active analogs, 5f, 
5h, 5m and 5r were screened for in vivo anti-
tumor activity over EAC in mice, as well as in 
vitro cytotoxicity toward W138 normal cells. 
HDACs inhibitory activity of the new active 
compounds is a plausible mechanism that 
might shed light toward the discovery of a 
new class of HDACs inhibitors. 
 
MATERIALS AND METHODS 
Chemistry 
Stuart SMP10 melting point apparatus 
was utilized to determine melting points °C. 
Bruker Avance 400 MHz spectrometer was 
applied for recording 1H and 13C NMR spec-
tra; chemical shifts are expressed in δ ppm 
with reference to TMS (Georgia State Univer-
sity, USA). HRMS were obtained on nano 
LC-Q-TOF spectrometer in +ve or -ve ion 
mode (Georgia State University, USA). Ele-
mental analyses (C, H, N) were determined, 
and were within ± 0.4% of the calculated val-
ues (Georgia State University, USA). The 
completion of reactions was controlled utiliz-
ing TLC plates (silica gel 60 F254, Merck) 
and UV (366 nm) was used for visualization 
of the spots. Chloroform/methanol (9:1) and 
n-hexane/ethyl acetate (3:1) were utilized as 
elution solvents. 
 
Synthesis of 3-acetylcoumarin (2): Salicyl-
aldehyde (1) (2.20 g, 18 mmol), ethyl aceto-
acetate (3.12 g, 24 mmol) and piperidine (0.1 
mL) were heated in ethanol (5 mL) under mi-
crowave irradiation (50 W) at 45 °C for 5 min. 
The precipitated solid upon cooling was fil-
tered and crystallized from ethanol. Yield 
85%, m.p. 117-118 °C (Valizadeh et al., 
2007). 1H NMR (DMSO-d6) δ 2.40 (s, 2H, 
CH2), 7.40-8.00 (m, 4H, Ar-H), 8.80 (s, 1H, 
C4-H of chromone).  
 
Synthesis of 3-(bromoacetyl)coumarin (3): 
A solution of bromine (1.60 g, 20 mmol) was 
added dropwise with constant stirring to a so-
lution of compound 2 (2 g, 11 mmol) in chlo-
roform (15 mL). The mixture was stirred at 0-
5 °C for 6 hrs and the orange solid obtained 
was filtered and crystallized from glacial ace-
tic acid. Yield 63%, m.p. 161-162 °C (Sid-
diqui et al., 2009). 1H NMR (DMSO-d6) δ 
4.90 (s, 2H, CH2), 7.40-8.00 (m, 4H, Ar-H), 
8.80 (s, 1H, C4-H of chromone). 
 
Synthesis of 2-arylidenehydrazinocarbo-
thioamides 4a-t: Thiosemicarbazide (0.092 
g, 1 mmol), aromatic aldehyde (1 mmol) and 
glacial acetic acid (0.1 mL) were heated in 
ethanol (10 mL) under microwave irradiation 
(50 W) at 80 °C for 10 min. The precipitate 
formed upon cooling was filtered and crystal-
lized to afford 4a-t. 
 
2-(2-Bromobenzylidene)hydrazinocarbo-
thioamide (4a): Yield 84%, m.p. 202-203 °C 
(Coxon et al., 2013), (ethyl acetate/ethanol 
(3:1)), C8H8BrN3S. 1H NMR (DMSO-d6) δ 
7.25-8.45 (m, 7H, Ar-H, NH2, CH=N), 11.65 
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(s, 1H, NH). 13C NMR (DMSO-d6) δ 124.0, 
128.1, 128.2, 131.8, 133.3, 133.4, 141.2, 
178.6. 
 
2-(2-Cyanobenzylidene)hydrazinocarbo-
thioamide (4b): Yield 91%, m.p. 212-213 °C 
(Hernandez et al., 2010), (chloroform), 
C9H8N4S. 1H NMR (DMSO-d6) δ 7.60-8.55 
(m, 7H, Ar-H, CH=N, NH2), 11.85 (s, 1H, 
NH). 
 
2-(3-Cyanobenzylidene)hydrazinocarbo-
thioamide (4c): Yield 82%, m.p. 204-205 °C 
(Hernandez et al., 2008), (ethanol/water 
(2:1)), C9H8N4S. 1H NMR (DMSO-d6) δ 7.55-
8.45 (m, 7H, Ar-H, CH=N, NH2), 11.60 (s, 
1H, NH). 13C NMR (DMSO-d6) δ 112.1, 
116.6, 130.2, 132.1, 133.7, 134.1, 134.6, 
144.3, 177.9. 
 
2-(4-(Trifluoromethyl)benzylidene)hydra-
zinocarbothioamide (4d): Yield 79%, m.p. 
169-170 °C (Bernstein et al., 1951), (ethyl ac-
etate/ethanol (3:1)), C9H8F3N3S. 1H NMR 
(DMSO-d6) δ 7.75-8.45 (m, 7H, Ar-H, NH2, 
CH=N), 11.65 (s, 1H, NH). 13C NMR 
(DMSO-d6) δ 123.2, 125.8, 128.2, 130.0, 
138.6, 144.2, 178.8. 
 
2-(3-Methylbenzylidene)hydrazinocar-
bothioamide (4e): Yield 79%, m.p. 190-
191 °C (Lv et al., 2010), (methanol), 
C9H11N3S. 1H NMR (DMSO-d6) δ 2.45 (s, 
3H, CH3), 7.15-8.45 (m, 7H, Ar-H, NH2, 
CH=N), 11.40 (s, 1H, NH). 13C NMR 
(DMSO-d6) δ 23.6, 125.7, 127.9, 129.2, 
130.9, 133.6, 136.5, 144.1, 179.2. 
 
2-(2,6-Dichlorobenzylidene)hydrazinocar-
bothioamide (4f): Yield 81%, m.p. 236-
238 °C (Bernstein et al., 1951), (ethanol/wa-
ter (2:1)), C8H7Cl2N3S. 1H NMR (DMSO-d6) 
δ 7.30-8.50 (m, 6H, Ar-H, CH=N, NH2), 
11.75 (s, 1H, NH). 
 
2-(2-Chloro-6-fluorobenzylidene)hydrazi-
nocarbothioamide (4g): Yield 85%, m.p. 
241-242 °C (Sumangala et al., 2012), (ethyl 
acetate/ethanol (3:1)), C8H7ClFN3S. 1H NMR 
(DMSO-d6) δ 7.20-8.45 (m, 6H, Ar-H, NH2, 
CH=N), 11.75 (s, 1H, NH).  
 
2-(2-Chloro-5-nitrobenzylidene)hydrazi-
nocarbothioamide (4h): Yield 79%, m.p. 
207-208 °C (Hao, 2010), (ethanol /water 
(2:1)), C8H7ClN4O2S. 1H NMR (DMSO-d6) δ 
7.75-9.00 (m, 6H, Ar-H, CH=N, NH2), 11.80 
(s, 1H, NH). 13C NMR (DMSO-d6) δ 125.1, 
125.8, 129.6, 133.9, 141.2, 145.1, 146.9, 
179.1. 
 
2-(3-Bromo-4-hydroxybenzylidene)hydra-
zinocarbothioamide (4i): Yield 67%, m.p. 
169-172 °C (Tsurkan et al., 1982), (metha-
nol), C8H8BrN3OS. 1H NMR (DMSO-d6) δ 
6.95-8.20 (m, 6H, Ar-H, NH2, CH=N), 10.75 
(s, 1H, OH), 11.30 (s, 1H, NH). 
 
2-(2-Hydroxy-5-methylbenzylidene)hydra-
zinocarbothioamide (4j): Yield 72%, m.p. 
196-198 °C (Pahontu et al., 2013), (ethyl ace-
tate/ethanol (3:1)), C9H11N3OS. 1H NMR 
(DMSO-d6) δ 2.20 (s, 3H, CH3), 6.70-8.30 
(m, 6H, Ar-H, NH2, CH=N), 9.50 (s, 1H, 
OH), 11.30 (s, 1H, NH).  
 
2-(4-Hydroxy-3-methylbenzylidene)hydra-
zinocarbothioamide (4k): Yield 71%, m.p. 
173-175 °C, (ethyl acetate/ethanol (3:1)) 
(Kaishi, 1953), C9H11N3OS. 1H NMR 
(DMSO-d6) δ 2.15 (s, 3H, CH3), 6.85-8.05 
(m, 6H, Ar-H, NH2, CH=N), 9.85 (s, 1H, 
OH), 11.20 (s, 1H, NH).  
 
2-(2,4-Dimethoxybenzylidene)hydrazino-
carbothioamide (4l): Yield 69%, m.p. 221-
223 °C (Pasha et al., 2008), (ethanol/water 
(2:1)), C10H13N3O2S. 1H NMR (DMSO-d6) δ 
3.82 (s, 6H, 2OCH3), 6.60 (s, 2H, NH2), 7.85-
8.10 (m, 3H, Ar-H), 8.35 (s, 1H, CH=N), 
11.30 (s, 1H, NH).  
 
2-((1H-Pyrrol-2-yl)methylidene)hydra-
zinocarbothioamide (4m): Yield 84%, m.p. 
200-201 °C (Yi et al., 2011), (methanol), 
C6H8N4S. 1H NMR (DMSO-d6) δ 6.15-7.95 
(m, 5H, pyrrole-H, NH2), 7.90 (s, 1H, CH=N), 
11.20 (s, 1H, NH), 11.35 (s, 1H, NH). 
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2-((1,1'-Biphenyl)-4-ylmethylidene)hydra-
zinocarbothioamide (4n): Yield 80%, m.p. 
202-203 °C (Mendoza-Merono et al., 2010), 
(ethanol/water (2:1)), C14H13N3S. 1H NMR 
(DMSO-d6) δ 7.45-8.25 (m, 12H, Ar-H, NH2, 
CH=N), 11.50 (s, 1H, NH). 13C NMR 
(DMSO-d6) δ 127.1, 127.3, 128.2, 128.3, 
129.4, 133.7, 139.8, 141.7, 142.3, 178.4. 
 
2-(Naphthalen-2-ylmethylidene)hydra-
zinocarbothioamide (4o): Yield 88%, m.p. 
245-246 °C (Yi et al., 2011), (ethanol/water 
(2:1)), C12H11N3S. 1H NMR (DMSO-d6) δ 
7.10-8.70 (m, 10H, Ar-H, NH2, CH=N), 11.55 
(s, 1H, NH). 
 
2-((1-Nitronaphthalen-2-yl)methylidene)-
hydrazinocarbothioamide (4p): Yield 77%, 
m.p. 183-185 °C, (ethyl acetate/ethanol 
(3:1)). 1H NMR (DMSO-d6) δ 7.60-8.45 (m, 
9H, Ar-H, NH2, CH=N), 11.70 (s, 1H, NH). 
Anal. C12H10N4O2S  (C, H, N).  
 
2-((2-Oxo-2H-chromen-6-yl)methylidene)-
hydrazinocarbothioamide (4q): Yield 71%, 
m.p. 276-278 °C (Datta and Daniels, 1963), 
(methanol), C11H9N3O2S. 1H NMR (DMSO-
d6) δ 6.55-8.20 (m, 8H, Ar-H, C4-H of chro-
mone, NH2, CH=N), 11.55 (s, 1H, NH). 
 
2-((10-Chloroanthracen-9-yl)methyli-
dene)hydrazinocarbothioamide (4r): Yield 
81%, m.p. 195-197 °C, (ethyl acetate/ethanol 
(3:1)). 1H NMR (DMSO-d6) δ 7.70-8.65 (m, 
10H, Ar-H), 9.20 (s, 1H, CH=N), 11.85 (s, 
1H, NH). Anal. C16H12ClN3S (C, H, N).  
 
2-(Phenanthren-9-ylmethylidene)hydra-
zinocarbothioamide (4s): Yield 69%, m.p. 
219-220 °C (Ebrahimi et al., 2015), (etha-
nol/water (2:1)), C16H13N3S. 1H NMR 
(DMSO-d6) δ 7.65-8.95 (m, 12H, Ar-H, NH2, 
CH=N), 11.55 (s, 1H, NH). 13C NMR 
(DMSO-d6) δ 123.3, 123.9, 124.4, 127.4, 
127.7, 127.9, 128.0, 128.2, 128.4, 128.7, 
129.4, 130.5, 130.7, 131.2, 142.0, 178.4. 
 
2-(Pyren-2-ylmethylidene)hydrazinocar-
bothioamide (4t): Yield 83%, m.p. 200-202 
°C, (ethyl acetate/ethanol (3:1)). 1H NMR 
(DMSO-d6) δ 8.05-8.90 (m, 11H, Ar-H, 
NH2), 9.25 (s, 1H, CH=N), 11.65 (s, 1H, NH). 
Anal. C18H13N3S (C, H, N). 
 
Synthesis of hydrazinothiazolylcoumarin 
derivatives 5a-t: 3-(Bromoacetyl)coumarin 
(3) (0.107 g, 4 mmol), 2-arylidenehydrazino-
carbothioamides 4a-t (4 mmol) and glacial 
acetic acid (0.1 mL) were heated in ethanol 
(10 mL) under microwave irradiation (60 W) 
at 100 °C for 10 min. The attained solid was 
filtered and crystallized to give 5a-t. 
 
3-(2-(2-(2-Bromobenzylidene)hydrazino)-
thiazol-4-yl)-2H-chromen-2-one (5a): Yield 
75%, m.p. 212-213 °C, (ethanol/water (2:1)). 
1H NMR (DMSO-d6) δ 7.30-8.65 (m, 11H, 
Ar-H, C5-H of thiazole, C4-H of chromone, 
CH=N), 12.50 (s, 1H, NH). 13C NMR 
(DMSO-d6) δ 116.3, 119.6, 120.9, 123.1, 
125.2, 127.1, 128.6, 129.3, 129.9, 131.4, 
132.2, 133.4, 133.6, 138.7, 140.2, 144.5, 
152.8, 159.2, 167.9. HRMS: m/z (ESI) calcd 
for C19H11BrN3O2S-, [M-H]- : 423.9749; 
found: 423.9758. Anal. C19H12BrN3O2S (C, 
H, N).  
 
3-(2-(2-(2-Cyanobenzylidene)hydrazino)-
thiazol-4-yl)-2H-chromen-2-one (5b): 
Yield 69%, m.p. 219-220 °C, (ethanol/water 
(2:1)). 1H NMR (DMSO-d6) δ 7.30-8.80 (m, 
11H, Ar-H, C5-H of thiazole, C4-H of chro-
mone, CH=N), 12.55 (s, 1H, NH). 13C NMR 
(DMSO-d6) δ 112.3, 113.6, 116.1, 120.7, 
123.1, 125.2, 127.3, 128.9, 129.7, 129.9, 
131.7, 132.1, 132.9, 133.5, 138.2, 143.7, 
145.8, 152.6, 161.3, 168.4. HRMS: m/z (ESI) 
calcd for C20H11N4O2S-, [M-H]- : 371.0581; 
found: 371.0593. Anal. C20H12N4O2S (C, H, 
N).  
 
3-(2-(2-(3-Cyanobenzylidene)hydrazino)-
thiazol-4-yl)-2H-chromen-2-one (5c): Yield 
63%, m.p. 224-225 °C, (methanol). 1H NMR 
(DMSO-d6) δ 7.30-8.10 (m, 10H, Ar-H), 8.55 
(s, 1H, CH=N), 12.40 (s, 1H, NH). HRMS: 
m/z (ESI) calcd for C20H13N4O2S+, [M+H]+: 
EXCLI Journal 2017;16:1114-1131 – ISSN 1611-2156 
Received: February 10, 2017, accepted: July 31, 2017, published: August 30, 2017 
 
 
1119 
373.0785; found: 373.0766. Anal. 
C20H12N4O2S (C, H, N). 
 
3-(2-(2-(4-(Trifluoromethyl)benzylidene)-
hydrazino)thiazol-4-yl)-2H-chromen-2-
one (5d): Yield 72%, m.p. 189-190 °C, (eth-
anol/water (2:1)). 1H NMR (DMSO-d6) δ 
7.30-8.15 (m, 9H, Ar-H, C5-H of thiazole), 
8.30 (s, 1H, C4-H of chromone), 8.60 (s, 1H, 
CH=N), 12.45 (s, 1H, NH). 13C NMR 
(DMSO-d6) δ 111.5, 116.3, 119.6, 120.9, 
125.2, 126.1, 126.2, 127.4, 129.2, 129.3, 
132.2, 138.7, 140.3, 144.5, 152.7, 159.2, 
159.3, 167.9. HRMS: m/z (ESI) calcd for 
C20H11F3N3O2S-, [M-H]- : 414.0535; found: 
414.0541. Anal. C20H12F3N3O2S (C, H, N).   
 
3-(2-(2-(3-Methylbenzylidene)hydrazino)-
thiazol-4-yl)-2H-chromen-2-one (5e): Yield 
82%, m.p. 190-191 °C, (ethyl acetate/ethanol 
(3:1)). 1H NMR (DMSO-d6) δ 2.30 (s, 3H, 
CH3), 7.15-8.05 (m, 9H, Ar-H, C5-H of thia-
zole), 8.30 (s, 1H, C4-H of chromone), 8.52 
(s, 1H, CH=N), 12.20 (s, 1H, NH). 13C NMR 
(DMSO-d6) δ 21.4, 111.1, 116.3, 119.6, 
120.9, 121.6, 124.1, 125.2, 127.1, 129.2, 
129.3, 130.5, 132.1, 138.5, 138.6, 142.3, 
144.4, 152.7, 159.2, 168.1. HRMS: m/z (ESI) 
calcd for C20H14N3O2S-, [M-H]- : 360.0800; 
found: 360.0813. Anal. C20H15N3O2S (C, H, N). 
 
3-(2-(2-(2,6-Dichlorobenzylidene)hydra-
zino)thiazol-4-yl)-2H-chromen-2-one (5f): 
Yield 81%, m.p. 230-232 °C, (chloroform). 
1H NMR (DMSO-d6) δ 7.30-7.90 (m, 8H, Ar-
H, C5-H of thiazole), 8.30 (s, 1H, C4-H of 
chromone), 8.60 (s, 1H, CH=N), 12.50 (s, 1H, 
NH). 13C NMR (DMSO-d6) δ 111.7, 116.3, 
119.6, 120.9, 125.1, 125.3, 129.3, 130.9, 
132.1, 134.0, 136.8, 139.7, 144.4, 152.8, 
159.2, 159.3, 167.9. HRMS: m/z (ESI) calcd 
for C19H12Cl2N3O2S+, [M+H]+: 416.0034; 
found: 416.0030. Anal. C19H11Cl2N3O2S (C, 
H, N). 
 
3-(2-(2-(2-Chloro-6-fluorobenzylidene)hy-
drazino)thiazol-4-yl)-2H-chromen-2-one 
(5g): Yield 69%, m.p. 195-196 °C, (etha-
nol/water (2:1)). 1H NMR (DMSO-d6) δ 7.25-
7.90 (m, 8H, Ar-H, C5-H of thiazole), 8.25 (s, 
1H, C4-H of chromone), 8.65 (s, 1H, CH=N), 
12.50 (s, 1H, NH). 13C NMR (DMSO-d6) δ 
111.7, 115.9, 116.1, 119.6, 120.8, 120.9, 
125.2, 126.7, 126.8, 129.3, 133.4, 134.7, 
138.7, 144.4, 152.8, 159.2, 159.3, 161.9, 
167.9. HRMS: m/z (ESI) calcd for 
C19H12ClFN3O2S+, [M+H]+: 400.0328; 
found: 400.0314. Anal. C19H11ClFN3O2S (C, 
H, N).  
 
3-(2-(2-(2-Chloro-5-nitrobenzylidene)hy-
drazino)thiazol-4-yl)-2H-chromen-2-one 
(5h): Yield 74%, m.p. 176-177 °C, (etha-
nol/water (2:1)). 1H NMR (DMSO-d6) δ 7.30-
8.65 (m, 10H, Ar-H, C5-H of thiazole, C4-H 
of chromone, CH=N), 12.70 (s, 1H, NH). 13C 
NMR (DMSO-d6) δ 112.3, 120.9, 123.1, 
125.4, 125.7, 126.9, 127.2, 128.4, 129.3, 
129.9, 133.7, 138.1, 141.0, 142.8, 145.9, 
146.2, 151.3, 161.6, 169.2. HRMS: m/z (ESI) 
calcd for C19H12ClN4O4S+, [M+H]+: 
427.0246; found: 427.0267. Anal. 
C19H11ClN4O4S (C, H, N). 
 
3-(2-(2-(3-Bromo-4-hydroxybenzylidene)-
hydrazino)thiazol-4-yl)-2H-chromen-2-
one (5i): Yield 80 %, m.p. 182-184 °C, (ethyl 
acetate/ethanol (3:1)). 1H NMR (DMSO-d6) δ 
7.00-8.85 (m, 10H, Ar-H, C5-H of thiazole, 
C4-H of chromone, CH=N), 10.85 (s, 1H, 
OH), 12.05 (s, 1H, NH). HRMS: m/z (ESI) 
calcd for C19H11BrN3O3S-, [M-H]- : 
439.9685; found: 439.9698. Anal. 
C19H12BrN3O3S (C, H, N).  
 
3-(2-(2-(2-Hydroxy-5-methylbenzylidene)-
hydrazino)thiazol-4-yl)-2H-chromen-2-
one (5j): Yield 84%, m.p. 206-207 °C, (ethyl 
acetate/ethanol (3:1)). 1H NMR (DMSO-d6) δ 
2.20 (s, 3H, CH3), 6.80-7.90 (m, 8H, Ar-H, 
C5-H of thiazole), 8.30 (s, 1H, C4-H of chro-
mone), 8.55 (s, 1H, CH=N), 9.80 (s, 1H, OH), 
12.15 (s, 1H, NH). 13C NMR (DMSO-d6) δ 
20.6, 110.8, 116.3, 116.5, 119.6, 120.1, 120.9, 
125.2, 126.7, 128.4, 129.3, 131.8, 132.1, 
138.6, 140.6, 144.6, 152.8, 154.4, 159.2, 
167.8. HRMS: m/z (ESI) calcd for 
EXCLI Journal 2017;16:1114-1131 – ISSN 1611-2156 
Received: February 10, 2017, accepted: July 31, 2017, published: August 30, 2017 
 
 
1120 
C20H14N3O3S-, [M-H]- : 376.0781; found: 
376.0771. Anal. C20H15N3O3S (C, H, N). 
 
3-(2-(2-(4-Hydroxy-3-methylbenzylidene)-
hydrazino)thiazol-4-yl)-2H-chromen-2-
one (5k): Yield 71%, m.p. 193-194 °C, (eth-
anol/water (2:1)). 1H NMR (DMSO-d6) δ 2.15 
(s, 3H, CH3), 6.80 (s, 1H, C5-H of thiazole), 
7.25-7.95 (m, 8H, Ar-H, C4-H of chromone), 
8.50 (s, 1H, CH=N), 9.75 (s, 1H, OH), 11.90 
(s, 1H, NH). HRMS: m/z (ESI) calcd for 
C20H14N3O3S-, [M-H]- : 376.0781; found: 
376.0765. Anal. C20H15N3O3S (C, H, N). 
 
3-(2-(2-(2,4-Dimethoxybenzylidene)-hy-
drazino)thiazol-4-yl)-2H-chromen-2-one 
(5l): Yield 79%, m.p. 219-220 °C, (chloro-
form). 1H NMR (DMSO-d6) δ 3.80 (s, 3H, 
OCH3), 3.86 (s, 3H, OCH3), 6.65-8.55 (m, 
10H, Ar-H, C5-H of thiazole, C4-H of chro-
mone, CH=N), 11.90 (s, 1H, NH). 13C NMR 
(DMSO-d6) δ 56.1, 56.2, 102.3, 106.3, 111.3, 
115.6, 120.6, 121.8, 125.9, 126.6, 128.2, 
129.6, 132.3, 136.7, 144.1, 146.4, 151.3, 
159.6, 161.3, 163.5, 169.1. HRMS: m/z (ESI) 
calcd for C21H18N3O4S+, [M+H]+: 408.1037; 
found: 408.1025. Anal. C21H17N3O4S (C, H, 
N). 
 
3-(2-(2-((1H-Pyrrol-2-yl)methylidene)hy-
drazino)thiazol-4-yl)-2H-chromen-2-one 
(5m): Yield 62%, m.p. 167-168 °C, (chloro-
form). 1H NMR (DMSO-d6) δ 6.10-6.90 (m, 
4H, pyrrole-H, C5-H of thiazole), 7.30-7.95 
(m, 5H, Ar-H, C4-H of chromone), 8.55 (s, 
1H, CH=N), 11.30 (s, 1H, NH), 11.85 (s, 1H, 
NH). 13C NMR (DMSO-d6) δ 111.3, 113.7, 
116.6, 120.3, 120.9, 125.1, 125.6, 128.1, 
128.6, 129.7, 133.1, 139.4, 145.2, 146.3, 
155.4, 162.1, 170.9. HRMS: m/z (ESI) calcd 
for C17H11N4O2S-, [M-H]- : 335.0610; found: 
335.0619. Anal. C17H12N4O2S (C, H, N).  
 
3-(2-(2-((1,1'-Biphenyl)-4-ylmethylidene)-
hydrazino)thiazol-4-yl)-2H-chromen-2-
one (5n): Yield 77%, m.p. 198-200 °C, (ethyl 
acetate/ethanol (3:1)). 1H NMR (DMSO-d6) δ 
7.30-8.65 (m, 16H, Ar-H, C5-H of thiazole, 
C4-H of chromone, CH=N), 12.25 (s, 1H, 
NH). 13C NMR (DMSO-d6) δ 111.2, 116.4, 
119.6, 121.0, 125.2, 127.1, 127.4, 127.5, 
128.3, 129.3, 129.5, 132.2, 133.8, 138.7, 
139.8, 141.3, 141.8, 144.5, 152.8, 159.3, 
168.2. HRMS: m/z (ESI) calcd for 
C25H16N3O2S-, [M-H]- : 422.0955; found: 
422.0959. Anal. C25H17N3O2S (C, H, N). 
 
3-(2-(2-(Naphthalen-2-ylmethylidene)hy-
drazino)thiazol-4-yl)-2H-chromen-2-one 
(5o): Yield 79%, m.p. 225-227 °C, (ethyl ac-
etate/ethanol (3:1)). 1H NMR (DMSO-d6) δ 
7.30-8.60 (m, 14H, Ar-H, C5-H of thiazole, 
C4-H of chromone, CH=N), 12.30 (s, 1H, 
NH). HRMS: m/z (ESI) calcd for 
C23H14N3O2S-, [M-H]- : 396.0812; found: 
396.0795. Anal. C23H15N3O2S (C, H, N).  
 
3-(2-(2-((1-Nitronaphthalen-2-yl)methyli-
dene)hydrazino)thiazol-4-yl)-2H-
chromen-2-one (5p): Yield 63%. m.p. 211-
213 °C, (chloroform). 1H NMR (DMSO-d6) δ 
7.35-8.25 (m, 12H, Ar-H, C5-H of thiazole, 
C4-H of chromone), 8.55 (s, 1H, CH=N), 
12.75 (s, 1H, NH). 13C NMR (DMSO-d6) δ 
113.2, 115.9, 121.1, 123.6, 124.2, 125.1, 
125.7, 126.3, 127.3, 127.6, 128.4, 128.9, 
129.5, 129.8, 135.2, 137.4, 142.9, 144.6, 
145.9, 147.2, 154.3, 162.2, 171.7. HRMS: m/z 
(ESI) calcd for C23H13N4O4S-, [M-H]- : 
441.0663; found: 441.0660. Anal. 
C23H14N4O4S (C, H, N).  
 
6-((2-(4-(2-Oxo-2H-chromen-3-yl)thiazol-
2-yl)hydrazono)methyl)-2H-chromen-2-
one (5q): Yield 76%, m.p. 181-183 °C, (eth-
anol/water (2:1)). 1H NMR (DMSO-d6) δ 6.50 
(d, 1H, C3-H of chromone), 7.30-8.15 (m, 
10H, Ar-H, C5-H of thiazole, C4-H of two 
chromone moieties), 8.55 (s, 1H, CH=N), 
12.25 (s, 1H, NH). 13C NMR (DMSO-d6) δ 
111.2, 116.3, 117.2, 117.5, 119.5, 119.6, 
120.9, 125.2, 126.7, 129.2, 129.7, 131.2, 
132.2, 138.6, 140.6, 144.5, 151.9, 152.7, 
154.3, 159.2, 160.1, 168.0. HRMS: m/z (ESI) 
calcd for C22H12N3O4S-, [M-H]- : 414.0560; 
found: 414.0565. Anal. C22H13N3O4S (C, H, 
N).  
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3-(2-(2-((10-Chloroanthracen-9-yl)-me-
thylidene)hydrazino)thiazol-4-yl)-2H-
chromen-2-one (5r): Yield 86%, m.p. 238-
240 °C, (ethanol/water (2:1)). 1H NMR 
(DMSO-d6) δ 7.20-8.75 (m, 15H, Ar-H, C5-H 
of thiazole, C4-H of chromone, CH=N), 12.50 
(s, 1H, NH). 13C NMR (DMSO-d6) δ 111.3, 
116.4, 120.4, 122.5, 125.1, 125.2, 125.9, 
126.7, 127.8, 128.4, 128.8, 129.3, 130.1, 
132.5, 134.0, 138.8, 140.1, 142.3, 152.0, 
164.2, 168.0. HRMS: m/z (ESI) calcd for 
C27H15ClN3O2S-, [M-H]- : 480.0574; found: 
480.0574. Anal. C27H16ClN3O2S (C, H, N).  
 
3-(2-(2-(Phenanthren-9-ylmethylidene)-
hydrazino)thiazol-4-yl)-2H-chromen-2-
one (5s): Yield 87%, m.p. 245-247 °C, (chlo-
roform). 1H NMR (DMSO-d6) δ 7.30-8.20 
(m, 11H, Ar-H, C5-H of thiazole, C4-H of 
chromone, CH=N), 8.55-9.10 (m, 5H, Ar-H), 
12.45 (s, 1H, NH). HRMS: m/z (ESI) calcd for 
C27H16N3O2S-, [M-H]- : 446.0941; found: 
446.0960. Anal. C27H17N3O2S (C, H, N).  
 
3-(2-(2-(Pyren-2-ylmethylidene)hydra-
zino) thiazol-4-yl)-2H-chromen-2-one (5t): 
Yield 89%, m.p. 237-239 °C, (ethanol/water 
(2:1)). 1H NMR (DMSO-d6) δ 7.35-9.00 (m, 
16H, Ar-H, C5-H of thiazole, C4-H of chro-
mone, CH=N), 12.50 (s, 1H, NH). HRMS: 
m/z (ESI) calcd for C29H16N3O2S-, [M-H]- : 
470.0975; found: 470.0979. Anal. 
C29H17N3O2S (C, H, N).  
 
Biology  
Detailed biological screening methods are 
provided in the supplementary information.  
In vitro antitumor assay 
The new analogs were tested for in vitro 
antitumor efficacy adopting the reported pro-
cedure (Mosmann, 1983; Denizot and Lang, 
1986; Gerlier and Thomasset, 1986).  
In vivo antitumor assay 
In vivo antitumor assessment of 5f, 5h, 5m 
and 5r was performed according to the litera-
ture method (Oberling and Guerin, 1954; 
Sheeja et al., 1997; Clarkson and Burchenal, 
1965). 
In vitro cytotoxicity testing 
In vitro cytotoxic activity of 5f, 5h, 5m 
and 5r was evaluated in accord to the reported 
method (Mosmann, 1983; Denizot and Lang, 
1986; Gerlier and Thomasset, 1986). 
 
RESULTS AND DISCUSSION  
Chemistry 
3-(Bromoacetyl)coumarin (3) was synthe-
sized via a two step procedure (Figure 2). 
First, cyclocondensation of salicylaldehyde 
(1) and ethyl acetoacetate under microwave 
irradiation utilizing piperidine as a catalyst to 
give the 3-acetylcoumarin (2) (Valizadeh et 
al., 2007). Second, bromination of compound 
2 in chloroform to yield the bromoketone 3 in 
63% yield (Siddiqui et al., 2009) (Figure 2). 
The 2-arylidenehydrazinocarbothioamides 
4a-t were synthesized through condensation 
of the aromatic aldehydes and thiosemicarba-
zide in ethanol under microwave irradiation 
(Figure 3). Microwave irradiation of 4a-t and 
bromoketone 3 in ethanol, followed by addi-
tion of ammonium hydroxide 5%, furnished 
the desired thiazolylcoumarin hybrids 5a-t in 
moderate to good yields (62-89%) (Figure 3). 
 
 
 
Figure 2: Synthesis of 3-(bromoacetyl)coumarin (3) 
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Figure 3: Synthesis of thiazolylcoumarin hybrids 5a-t 
 
 
Biological screening  
In vitro antitumor screening 
In vitro antitumor screening of com-
pounds 5a-t was carried out on cervical 
(Hela) and kidney fibroblast (COS-7) cancer 
cell lines in accord to MTT assay (Mosmann, 
1983; Denizot and Lang, 1986; Gerlier and 
Thomasset, 1986) and utilizing doxorubicin 
as a standard drug. The concentrations of the 
compounds that cause 50% inhibition of cell 
viability (IC50, µM) were calculated. Com-
pounds 5f, 5h, 5m and 5r exhibited remarka-
ble activity against Hela cell line. In addition, 
5h and 5r displayed outstanding efficacy to-
ward COS-7 cell line (Table 1). The rest of the 
tested compounds displayed weaker efficacy.  
Structure-activity relationship  
Compound 5f incorporating 2,6-dichloro-
phenyl moiety displayed prominent antitumor 
efficacy toward Hela cell line and it repre-
sents the basic framework for further struc-
tural modifications. Replacing this moiety 
with 2-chloro-6-fluorophenyl counterpart  
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Table 1: In vitro antitumor activity of 5a-t toward Hela and COS-7 cancer cell lines 
  
Comp. No. IC50 (µM)  Comp. No. IC50 (µM) 
 Hela COS-7 Hela COS-7
5a >50  >50  5l >50 >50 
5b >50 >50 5m 6.25 12.50
5c >50 >50 5n >50  >50  
5d >50  >50  5o >50  >50 
5e >50  >50  5p >50  >50  
5f 1.90 >50  5q >50  >50 
5g >50  >50  5r 1.29 1.66
5h 1.42 1.96 5s >50  >50 
5i >50  >50  5t >50  >50  
5j >50  >50  Doxorubicin 2.05 3.04 
5k >50  >50  -------- -------- -------- 
Bold values refer to the good results 
 
 
abolished the activity against the same cell 
line (compound 5g), whereas its replacement 
with 2-chloro-5-nitrophenyl counterpart led 
to increased efficacy toward the same cell line 
and a tremendous improvement in the activity 
toward COS-7 cell line (compound 5h). In-
corporation of pyrrol-2-yl moiety into the thi-
azolylcoumarin resulted in considerable effi-
ciency toward Hela and COS-7 cell lines 
which might be attributed to additional inter-
action with the target receptor (compound 
5m). 10-Chloroanthracen-9-yl moiety was 
proved to exhibit the optimum hydrophobic 
binding affinity and displayed the most potent 
antitumor efficacy against both cell lines 
(compound 5r). 
In vivo antitumor screening 
Results of in vivo antitumor screening of 
compounds 5f, 5h, 5m and 5r (showing the 
highest in vitro antitumor activity) against 
EAC cells in mice are listed in Tables 2-4. 
The % increase in lifespan of EAC inoculated 
mice (%ILS), the decrease in viable tumor 
cell count and the retrieval of normal blood 
profile are three substantial measures used for 
estimation of antitumor efficacy of the se-
lected compounds and 5-fluorouracil (5-FU) 
(standard agent) (Oberling and Guerin, 1954; 
Sheeja et al., 1997; Clarkson and Burchenal, 
1965). The mean survival time (MST) of each 
group was rated and %ILS of mice inoculated 
with EAC cells was determined adopting the 
equation: %ILS = [(MST of treated group/ 
MST of positive control group)-1] x 100, 
where MST = days of the mouse in a 
group/total no. of mice. Compound 5r dis-
played prominent increase in lifespan of mice 
(Table 2). Also, this compound produced con-
siderable decrease in viable tumor cell count 
(Table 3). Regarding the effect on blood pro-
file, compound 5r showed higher Hb and 
RBC levels and lower WBC count than 5-FU 
(Table 4).  
 
Table 2: Effect of 5f, 5h, 5m and 5r on mean sur-
vival time and % increase in lifespan of mice inoc-
ulated with EAC cells 
Group Mean survival 
time (day) 
 % Increase 
in lifespan 
Normal nda nda 
EAC only 14.5 nda 
5f 41.0 182.7 
5h 39.3 171.0 
5m 37.0 155.2 
5r 45.5 213.8 
5-Fluorouracil 49.0 237.9 
a nd: not determined. 
Bold values refer to the good  results. 
 
Table 3: Effect of 5f, 5h, 5m and 5r on tumor vol-
ume and viable tumor cell count of mice inocu-
lated with EAC cells 
Group Tumor vol-
ume (mL) 
Viable tumor cell 
count/100 μL 
Normal nda nda 
EAC only 9.85 83.20x106
5f 2.62 25.83x106 
5h  3.12  32.57x106
5m 3.85 40.52x106 
5r 2.11 21.94x106
5-Fluorouracil 1.60 20.17x106 
a nd: not determined. 
Bold values refer to the good results.  
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Table 4: Effect of 5f, 5h, 5m and 5r on blood pro-
file of mice inoculated with EAC cells 
Group Hb 
(g/dl) 
RBCs 
Count 
106/mm3 
WBCs 
Count 
103/mm3 
Normal  13.73  5.84 5.99 
EAC only 8.15  3.69 23.96 
5f 12.92  5.14 8.41 
5h 11.97  4.92 9.25 
5m 11.43  4.39 9.61 
5r 13.10  5.55  7.45
5-Fluorouracil 12.96   5.21 8.86 
Bold values refer to the good results. 
 
In vitro cytotoxicity testing 
The effective antitumor compounds, 5f, 
5h, 5m and 5r were further assessed for in 
vitro cytotoxicity toward human normal lung 
fibroblast (W138) cell line (Mosmann, 1983; 
Denizot and Lang, 1986; Gerlier and Thomas-
set, 1986).  IC50 values (µM) of the tested 
compounds and 5-FU (reference cytotoxic 
agent) were calculated. Results (Table 5) re-
vealed that the four tested compounds are less 
cytotoxic than 5-FU. Comparing the IC50 val-
ues of 5h, 5m and 5r on the tested normal cell 
line (19.75-29.47 µM) with those on the 
tested cancer cell lines (1.29-12.50 µM), we 
can conclude that the three compounds are 
more selective cytotoxic agents toward cancer 
cells than normal cells. In addition, 5f was 
found to be more selective toward Hela can-
cer cell line (IC50 = 1.90 µM) than W138 nor-
mal cell line (IC50 = 36.21 µM). 
 
Table 5: In vitro cytotoxic activity of 5f, 5h, 5m and 
5r toward W138 normal cell line 
Comp. No. IC50 (µM)
5f 36.21 
5h 19.75 
5m 29.47 
5r 24.32 
5-Fluorouracil 5.73 
 
 
3D Pharmacophore elucidation 
A pharmacophore is a set of common 
structural features shared by a group of com-
pounds that interacts with the complementary 
sites on a specific target leading to biological 
activity (Rodolpho and Andrade, 2013). 
Based on this assumption, analysis of the mo-
lecular recognitions in the biological target in-
teracting with the lead compound will enable 
the design of more potent analogs. 
LigandScout software allows accurate vir-
tual screening based on 3D pharmacophore 
models, and it is utilized to produce a pharma-
cophore for trichostatin A (Wolber and 
Langer, 2005). The model (Figure 4) was gen-
erated by overlaying the pharmacophoric fea-
tures of HDAC8 domain complexed with tri-
chostatin A (PDB ID: 1T64) (PDB; 
http://www.rcsb.org/pdb/home/home.do). 
The pharmacophore created by Lig-
andScout revealed the presence of one hydro-
gen bond acceptor site (red arrow) embedded 
between five hydrophobic regions repre-
sented by yellow spheres which conveys the 
tremendous contribution of hydrophobic in-
teractions with the receptor. Moreover, ZBG 
represented by a blue conical shape, was ori-
ented at the terminal of the hydrophobic re-
gions and is proposed to be an essential fea-
ture in the presented pharmacophore. The 
four active antitumor compounds in this 
study, 5f, 5h, 5m and 5r were subjected to a 
pharmacophore-based virtual screening 
against the target pharmacophore of tri-
chostatin A. The matching pharmacophoric 
features between the active compounds and 
trichostatin A are identified in Table 6. All the 
active compounds attained a ZBG, a hydro-
gen bond acceptor site and at least two sites 
for hydrophobic interactions matching the 
orientation exhibited by the target pharmaco-
phore. In addition, a relative pharmacophore 
score illustrated in Table 6 was calculated for 
each compound. Compounds 5f and 5r exhib-
ited the highest relative pharmacophore score 
of 0.76 and 0.81, respectively. Figures 5A and 
6A illustrate the 3D alignments of 5f and 5r, 
respectively with the pharmacophore model. 
2D Mappings of the pharmacophore model 
with 5f and 5r are shown in Figures 5B and 
6B, respectively. The proposed pharmaco-
phore of HDAC8 revealed that hydrophobic 
forces represent the major contributing inter-
action with the compounds, accordingly, 
LeadIT program was utilized to examine the 
EXCLI Journal 2017;16:1114-1131 – ISSN 1611-2156 
Received: February 10, 2017, accepted: July 31, 2017, published: August 30, 2017 
 
 
1125 
hydrophobic interaction of the active analogs 
with the target receptor (Stahl and Rarey, 
2001). The lipophilic area of each compound 
exposed toward HDAC8 domain was given a 
score (Table 6). Compounds 5f and 5r at-
tained the highest lipophilic area score of -
14.12 and -14.65, respectively. 2D Interac-
tions of 5f and 5r with HDAC8 domain are 
presented in Figures 7 and 8, respectively. 
In silico studies 
Computational chemists follow different 
approaches for estimation of molecular diver-
sity. Drug-likeness is a qualitative notion used 
to study how a particular substance is "drug-
like". So, computer softwares were utilized 
for predicting the drug-likeness of the new 
drugs (Ursu et al., 2011). The most active 
compounds, 5f, 5h, 5m and 5r were studied 
for the expectation of Lipinski’s rule 
(Lipinski et al., 2001) along with other molec-
ular properties.  
 
 
Table 6: Results of pharmacophore analysis of 5f, 5h, 5m and 5r  
Comp. No. Matching Features Relative Pharmacophore  
Score 
Lipophilic Area 
Score 
5f        0.76 -14.12
5h      0.56 -13.71 
5m        0.54 -12.31 
5r        0.81 -14.65
Trichostatin A         1.00 -14.71 
: Hydrophobic region; : Zinc binding group;  : Hydrogen acceptor 
Bold values refer to the good results. 
 
 
Figure 4: A. LigandScout 3D proposed docking pose for trichostatin A in HDAC8 domain (PDB ID: 
1T64). B. 3D Pharmacophore of trichostatin A (in ball and stick presentation); The pharmacophore color 
coding is red for hydrogen acceptor, yellow for hydrophobic regions, and blue for zinc binding group. C. 
2D Representation of the pharmacophoric features of trichostatin A. D. The 3D pharmacophore model 
for HDAC8 domain (PDB ID: 1T64). The pharmacophore color coding is red for hydrogen acceptor, 
yellow for hydrophobic regions, and blue for zinc binding group 
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Figure 5: The 3D and 2D alignments of 5f with HDAC8 pharmacophore model. A. 3D Alignment of 5f 
with HDAC8 pharmacophore model. The pharmacophore color coding is red for hydrogen acceptors, 
yellow for hydrophobic regions and blue for zinc binding groups. B. 2D Representation of structural 
features of 5f that can be aligned with the pharmacophore hypothesis. HBA; hydrogen bond acceptor 
and H; hydrophobic center 
 
Figure 6: The 3D and 2D alignments of 5r with HDAC8 pharmacophore model. A. 3D Alignment of 5r 
with HDAC8 pharmacophore model. The pharmacophore color coding is red for hydrogen acceptors, 
yellow for hydrophobic regions and blue for zinc binding groups. B. 2D Representation of structural 
features of 5r that can be aligned with the pharmacophore hypothesis. HBA; hydrogen bond acceptor 
and H; hydrophobic center 
 
 
Figure 7: 2D Interaction of 5f with HDAC8 do-
main. Hydrogen bonds are shown by dashed 
lines. Green solid lines represent hydrophobic in-
teractions  
 
Figure 8: 2D Interaction of 5r with HDAC8 do-
main. Hydrogen bonds are shown by dashed 
lines. Green solid lines represent hydrophobic in-
teractions 
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Molinspiration calculations 
Lipinski’s rule is related to drug absorp-
tion (Lipinski et al., 2001). Also, topological 
polar surface area (TPSA) and number of ro-
tatable bonds (Nrotb) influence oral absorp-
tion of drugs (Veber et al., 2002).  
TPSA, Nrotb, and the parameters of 
Lipinski’s rule for the effective analogs, 5f, 
5h, 5m and 5r were evaluated using molinspi-
ration software.  
Results illustrated that all examined ana-
logs have zero or one violation of Lipinski’s 
rule, as well as TPSA values and Nrotb under 
the acceptable norms; therefore, they are an-
ticipated to be well absorbed (Table 7). 
Drug-likeness 
Osiris software (Jarrahpour et al., 2011) 
was applied for studying the toxicity hazards 
(mutagenicity, tumorigenicity, irritation & re-
productive effects) and drug-likeness of the 
analyzed compounds. Results revealed that all 
the analyzed analogs are expected to have no 
toxicity hazards. It is well established that 
molecules containing fragments which are ex-
tremely available in commercial drugs, have 
positive drug-likeness values. Results listed in 
Table 7 showed that 5f, 5m and 5r have posi-
tive drug-likeness values, and they are ex-
pected to have fragments which are available 
in commercial drugs. 
CONCLUSION 
The recent study led to the development 
of new efficient antitumor thiazolylcoumarin 
derivatives. Compounds 5f, 5h, 5m and 5r are 
the most active antitumor analogs toward 
Hela cell line; in addition, 5h and 5r dis-
played eminent activity toward COS-7 cell 
line. Moreover, 5r displayed the highest in 
vivo activity. Furthermore, the four active an-
alogs were proved to be less cytotoxic than 5-
FU on W138 normal cells; therefore, they 
might be used as potent antitumor agents with 
low toxicity toward normal cells. Further 
mechanistic and kinetic investigations con-
cerning the HDACs inhibitory activity of 
these active compounds will shed light on 
possible structural modifications desired to 
obtain new more active antitumor agents. 
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Table 7: TPSA, Nrotb, calculated Lipinski’s rule and drug-likeness of 5f, 5h, 5m and 5r 
Comp. No. Molecular properties Drug- 
likeness TPSA Nrotb miLogP nOH-NH nO-N M. wt. No. of  
violations 
5f 67.49 4 5.22 1 5 416.29 1 6.17 
5h 113.32 5 4.53 1 8 426.84 0 -1.13 
5m 83.28 4 3.12 2 6 336.38 0 5.43 
5r 67.49 4 6.86 1 5 481.96 1 5.23 
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